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Abstract
Background: Brucellosis, a zoonotic infection caused by one of the Gram-negative intracellular bacteria of the Brucella
genus, is an ongoing public health problem in Peru´. While most patients who receive standard antibiotic treatment recover,
5–40% suffer a brucellosis relapse. In this study, we examined the ex vivo immune cytokine profiles of recovered patients
with a history of acute and relapsing brucellosis.
Methodology/Principal Findings: Blood was taken from healthy control donors, patients with a history of acute brucellosis,
or patients with a history of relapsing brucellosis. Peripheral blood mononuclear cells were isolated and remained in culture
without stimulation or were stimulated with a panel of toll-like receptor agonists or heat-killed Brucella melitensis (HKBM)
isolates. Innate immune cytokine gene expression and protein secretion were measured by quantitative real-time
polymerase chain reaction and a multiplex bead-based immunoassay, respectively. Acute and relapse patients demon-
strated consistently elevated cytokine gene expression and secretion levels compared to controls. Notably, these include:
basal and stimulus-induced expression of GM-CSF, TNF-a, and IFN-c in response to LPS and HKBM; basal secretion of IL-6, IL-
8, and TNF-a; and HKBM or Rev1-induced secretion of IL-1b, IL-2, GM-CSF, IFN-U, and TNF-a. Although acute and relapse
patients were largely indistinguishable by their cytokine gene expression profiles, we identified a robust cytokine secretion
signature that accurately discriminates acute from relapse patients. This signature consists of basal IL-6 secretion, IL-1b, IL-2,
and TNF-a secretion in response to LPS and HKBM, and IFN-c secretion in response to HKBM.
Conclusions/Significance: This work demonstrates that informative cytokine variations in brucellosis patients can be
detected using an ex vivo assay system and used to identify patients with differing infection histories. Targeted diagnosis of
this signature may allow for better follow-up care of brucellosis patients through improved identification of patients at risk
for relapse.
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Introduction
Brucellosis in humans is a zoonotic infection caused by Gram-
negative facultative intracellular bacteria of the Brucella genus.
Four species are typically responsible for human infections, B.
abortus, B. melitensis, B. suis, and B. canis, and are transmitted from
animal reservoirs including infected cows, goats or sheep, pigs, and
dogs, respectively. Infection occurs by ingestion of contaminated
unpasteurized milk or cheese or through contact with blood or
materials from infected animals [1]. B. melitensis is recognized as
not only the most virulent species, needing only a few organisms
(10–100) to establish infection, but also the predominant species
responsible for the brucellosis burden in Peru´ [2,3]. Brucella spp.
are of particular interest because they are easily aerosolized, which
is underscored by the designation of brucellosis as the most
common laboratory-acquired infection [4] and Brucella spp. as a
category B agent on the Centers for Disease Control bioterrorism
hazard list.
Approximately 5–40% of patients treated for brucellosis suffer a
relapse, with the wide variation in risk historically being attributed
to the duration and combination of antibiotic treatment [5].
However, few investigations have focused on the variation of the
innate immune reaction to Brucella spp. and its impact on the rate
of relapse. While studies have examined the association of genetic
polymorphisms in cytokines and other immunity-related genes
with brucellosis susceptibility [6,7], less emphasis has been placed
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on the overall functional cytokine reaction of patients who
demonstrate brucellosis susceptibility or relapse.
Brucella spp. are able to survive and replicate within macro-
phages, and effective control of brucellosis requires a potent Th1
response to activate cellular mediated immunity which is driven by
the production of IFN-c, IL-2, and TNF-a [8–12]. A Th2
response, driven by IL-4 and IL-10, is detrimental to combating
brucellosis as it promotes humoral immunity and suppresses
macrophage activation [13,14].
In this study, we examined the ex vivo cytokine profiles of
patients with a history of brucellosis in the absence of stimuli and
after toll-like receptor (TLR) and heat-killed Brucella melitensis
(HKBM) stimulation. This approach is unique because we assessed
human cytokine expression and secretion in fully recovered patient
blood cells to determine if there is a brucellosis cytokine signature
present at baseline, that may underlie a person’s response to B.
melitensis infection. While previous studies employ animal models,
cell lines, or look at post-treatment serum cytokine levels [15], we
assessed the ex vivo immune reaction of primary cells from human
patients. We found that several cytokines showed altered
expression and secretion in both unstimulated and stimulated
conditions. Patients with a history of acute or relapsing brucellosis
can be accurately identified by a robust inflammatory cytokine
signature, months and even years after successful treatment. This
signature consists of increased secretion of TNF-a and IL-2 in
response to HKBM and LPS, IL-1b in response to Rev1 and LPS,
IFN-c in response to HKBM, and basal IL-6. This work
demonstrates that cytokine variations in brucellosis patients can
be detected using an ex vivo assay system and can be used to
distinguish between relapse and acute patients. Targeted diagnosis
of this signature may allow for improved treatment of brucellosis
by identifying patients at risk for relapse.
Methods
Ethics
The study was approved by the Human Research Protection
Program of the University of California, San Diego, and the
Comite´ de E´tica of Universidad Peruana Cayetano Heredia
(UPCH), Lima, Peru´. All patients provided written informed
consent prior to enrollment in the study.
Patients and healthy volunteers
Sixteen patients with a previously confirmed history of acute
brucellosis (6 males and 10 females; 44.8612.5 years, ‘‘acute’’) and
6 patients previously diagnosed with relapsing brucellosis (2 male
and 5 females; 39615.2 years, ‘‘relapse’’) were enrolled in the
study. Brucellosis was confirmed by serology, positive culture, or
both methods (Supporting Table S1). At the time of sample
collection all patients were 18 years of age or older, had completed
treatment and were asymptomatic for brucellosis for 6 months or
more, had a normal physical examination, and showed no signs or
symptoms of other illness. 11 healthy volunteers with no history of
brucellosis were also enrolled as negative controls (5 males and 6
females; 30.867.3 years, ‘‘control’’).
Volunteers provided 120 mL of venous blood or underwent
leukapheresis. Peripheral blood mononuclear cells (PBMCs) were
isolated using Ficoll Paque (GE Healthcare) as previously
described [16].
Ex vivo cell culture
Isolated PBMCs were cultured in RPMI-1640 (Sigma) with
10% fetal bovine serum at a density of 2.56106 cells per well of
a 24-well plate at 37uC with 5% CO2. After isolation, cells were
allowed to rest for 4 hours and were then stimulated with either
PBS (resting, basal), a TLR4 agonist, lipopolysaccharide B5:055
from Escherichia coli (LPS, 1 mg/ml, Sigma), a TLR2/1 agonist,
the synthetic triacylated lipoprotein Pam3CSK4 (1 mg/ml), a
TLR3 agonist, low molecular weight polyinosine-polycytidylic
acid (Poly(I:C), 10 mg/ml), a TLR7/8 agonist, the imidazoqui-
noline compound R848 (3 mg/ml), a TLR9 agonist, the
synthetic CpG ODN 1668 (CpG, 5 mM), heat-killed Brucella
melitensis vaccine strain Rev1 (Rev1, 65 CFU/ml) or a heat-
killed, virulent B. melitensis patient isolate (HKBM, 65 CFU/ml).
All manipulations of live Brucella melitensis vaccine strain Rev1
and the B. melitensis patient isolate were carried out under BSL3
conditions at UPCH, Lima, Peru. After 18 h of stimulation, the
supernatant was removed and preserved at 280uC and the cells
were washed with PBS and frozen for subsequent RNA
isolation.
RNA extraction and cDNA synthesis
After the culture supernatant was removed, PBMCs were
washed in PBS, centrifuged, and the cell pellets were frozen at
280uC. Cells were thawed, lysed, homogenized, and total RNA
was extracted using the QIAshredder and RNeasy kits per the
manufacturer’s instructions (Qiagen). RNA was eluted in 30 ml of
RNase-free water, and 1 mg was reverse-transcribed into cDNA
using the iScript cDNA synthesis kit according to the manufac-
turer’s instruction (Bio-Rad).
Quantitative real-time PCR and gene expression
Quantitative real-time PCR (qPCR) was performed to
measure the mRNA expression level of the housekeeping gene
GAPDH, and several inflammatory cytokines (GM-CSF, IFN-c,
IL-1b, IL-10 and TNF-a). Using a CFX384 Real-Time
Detection System (Bio-Rad), each reaction was performed in
triplicate in a final reaction volume of 5 ml, including 2.5 ml
SsoAdvanced SYBR Green Supermix (Bio-Rad), 1.0 ml cDNA
template, and 1.0 ml (100 nM final concentration) of each
primer. Primers were designed for each gene using Primer3
(Supporting Table S2). After amplification, threshold cycle (CT)
values were generated using the Bio-Rad CFX Manager
Software 1.6. The fold change of gene expression was calculated
as previously described [17].
Author Summary
Brucellosis is a disease caused by transmission of bacteria
of the Brucella genus from infected animals to humans.
The main route of infection occurs through consumption
of contaminated dairy products or contact with infected
animals. While most patients treated with antibiotics will
be cured of the infection, between 5–40% of patients
experience a relapse of brucellosis. The mechanisms
underlying these recurring infections remain poorly
understood. In this study, we examined blood cells from
control donors, patients who previously had acute
infections, and patients who previously had relapsing
infections. We identified an inflammatory cytokine signa-
ture from measurements of unstimulated and stimulated
cells that showed statistically significant differences
between relapsing and non-relapsing brucellosis patients.
Future applications of this assay system may allow for
better follow-up care of brucellosis through the diagnosis
of this cytokine signature and predictive or improved
identification of patients at risk for relapse.
Ex Vivo Cytokine Signature of Brucellosis
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Cytokine protein secretion levels
A multiplex bead-based immunoassay was used to quantify
cytokine levels secreted into the culture supernatant after
stimulation. Using the Human Cytokine 10-Plex Panel for the
Luminex platform, the following cytokines were measured
according to the manufacturer’s instruction: GM-CSF, IFN-c,
IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10 and TNF-a (Invitrogen).
Briefly, either recombinant protein standards or 50 ml of each
culture supernatant sample were first incubated, in duplicate, with
antibody-conjugated fluorophore beads, and then with protein-
specific biotinylated antibodies. Finally, following the addition of
Streptavidin-RPE, samples were analyzed using the Bio-Plex 200
system (Bio-Rad). Data analysis was performed using the
manufacturer provided software and the included recombinant
proteins were used to generate standard curves to determine the
sensitivity of the assay.
Statistical methods
Significance values were calculated using the R software
environment for statistical computing. For each pairwise compar-
ison, Welch’s t-test was used to estimate the probability that the
two samples have equal mean. Probabilities less than 0.05 suggest
significant differences between the two samples and are indicated
by an asterisk.
Classification and model selection
Prior to classification, all response variables were log10
transformed, centered, and scaled to unit variance. Unless
otherwise stated, variables for which more than four patients
were missing, or for which two or more patients belonging to the
same category were missing, were discarded. Missing values in the
remaining 70 response variables were imputed from their
conditional means [18]. Specifically, for each missing value, a
linear regression model was identified by forward model selection
using Akaike’s information criterion (AIC). Regressors were
chosen from the 32 response variables for which no data was
missing, including patient category. Forward selection was
terminated when there was no further reduction in the AIC, or
when the complexity of the model reached 12 regressors.
Imputation by conditional means was chosen because of the
relatively high correlation observed between variables [19,20].
Linear discriminant analysis (LDA) was performed in R using
the ‘lda’ function. Accuracy of the resulting linear discriminant
function, or classifier, was then assessed using the ‘predict’ function
in conjunction with leave-one-out cross-validation. To identify the
optimal classifier for a given cross-section of the data, LDA was
performed using all pairwise combinations of variables contained
in the cross-section. Top-performing pairs, defined as those pairs
of variables that trained a classifier with the highest accuracy, were
then used to seed model selection. During model selection, a
variable was chosen at each step whose inclusion in the classifier
resulted in the greatest increase in accuracy, up to a backtracking
factor of 0.03 (1 patient). Since a multiplicity of models could
satisfy this selection criteria, each selection was performed 20
times. The model ultimately identified by forward selection was
taken to be that which yielded the highest classification accuracy
while using the fewest number of variables.
Results
Inflammatory cytokine gene expression is increased in
brucellosis relapse patients
To quantify the induction of cytokine gene expression in
response to inflammatory stimuli, we first measured the resting, or
basal, expression in unstimulated PBMCs. We found that basal
expression of IL-1b and GM-CSF was significantly higher in
relapse patients than in controls, while TNF-a was significantly
higher in both acute and relapse patients compared to control
(<figref rids="‘LPS, relapse patients exhibited higher expression of
GM-CSF and IL-10 and significantly higher TNF-a and IFN-c
than either controls or acute patients (Figure 2A). This trend was
also observed in response to HKBM, except relapse and acute
patients exhibited similarly and significantly elevated levels of GM-
CSF, TNF-a, and IL-10 (Figure 2B). Thus while cytokine gene
expression in response to LPS appears to discriminate well
between relapse and either acute or controls, the response to
HKBM appears to discriminate between control subjects and
either acute or relapse patients.
In summary, relapse patients uniquely demonstrated elevated
basal IL-1b and GM-CSF expression compared to control donors.
In comparison to both acute and control donors, relapse patients
exhibit increased IFN-c expression after HKBM stimulation and
increased TNF-a expression after LPS.
Figure 1. Basal PBMC cytokine gene expression. Relative basal
amounts of IL-1b, GM-CSF, TNF-a, IFN-c, and IL-10 mRNA compared to
the housekeeping gene GAPDH (DCT) in unstimulated PBMCs from
control donors or acute or relapse brucellosis patients (asterisk indicates
p#0.05).
doi:10.1371/journal.pntd.0002424.g001
Figure 2. PBMC cytokine gene expression after stimulation.
Fold change of gene expression for IL-1b, GM-CSF, TNF-a, IFN-c and IL-
10 in PBMCs from control donors or acute or relapse brucellosis patients
after stimulation with (A) LPS (B) Heat-killed B. melitensis or (C) R848
(asterisk indicates p#0.05).
doi:10.1371/journal.pntd.0002424.g002
Ex Vivo Cytokine Signature of Brucellosis
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Inflammatory cytokine secretion is elevated in brucellosis
relapse patients
To test whether the differences observed in cytokine gene
expression were also manifest in the synthesis and secretion of
cytokine proteins, we used a multiplex bead-based immunoassay
to quantify ex vivo cytokine secretion in the culture supernatant of
unstimulated and stimulated PBMCs. We measured the concen-
trations of GM-CSF, IFN-c, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8,
IL-10, and TNF-a. In unstimulated cells we found that the basal
secretion of IL-6, IL-8, and TNF-a was elevated in both acute and
relapse patients compared to control subjects. IL-8 was higher in
relapse patients than in acute patients, while basal IL-2 was
increased in relapse patients compared to controls (Figure 3). All
differences were significant (p,0.05).
Next we stimulated PMBCs with LPS, heat-killed B. melitensis
(HKBM) or heat-killed B. melitensis vaccine strain Rev1 (Rev1). As
observed in our gene expression data, after stimulating with
HKBM, Rev1, or LPS, secretion of GM-CSF, IFN-c, and TNF-a
was significantly elevated in relapse patients compared to control
subjects (Figure 4). Additionally, IL-1b and IL-2 secretion was
significantly elevated in acute and relapse patients compared to
control donors after both HKBM and Rev1, but not LPS,
stimulation. Several of the cytokine concentrations measured in
response to other stimuli fell out of the observable range of the
assay (Supporting Figure S1).
A robust cytokine signature accurately distinguishes
relapsing from non-relapsing patients and controls
To test whether the differences observed in cytokine gene
expression and protein secretion were sufficient to accurately
discriminate between patients that did and did not experience a
relapse in brucellosis, we trained a linear discriminant classifier
using different cross-sections of the data and assessed its accuracy
by leave-one-out cross validation. Linear discriminant analysis
(LDA) is a supervised learning method that maximizes separation
in the data – defined here as the ratio of variances between patient
categories to the variance within – using a linear recombination of
response variables, in this case our observed gene expression or
cytokine secretion measurements. Using LDA in conjunction with
a model selection strategy allowed us to ask whether a subset of the
response variables that we assayed could accurately classify
patients as control, acute, or relapse.
First, cross-sections of the cytokine gene expression and protein
secretion data were chosen such that all response variables were of
the same cytokine or generated using the same stimulus. We refer
to these as ‘‘cytokine’’ and ‘‘stimulus’’ cross-sections, respectively.
A classifier trained on a cytokine cross-section is said to be trained
‘‘across stimuli’’, and vice versa. Response variables for which more
than four patients were missing, or for which two or more patients
belonging to the same category were missing, were discarded.
Missing values in the remaining 70 response variables were
imputed from their conditional means [18]. Linear discriminant
functions were then identified for each cross-section using a
forward model selection strategy with backtracking (see Methods).
On average, we found that higher classification accuracy was
achieved by training across stimuli than across cytokines. Training
across the four gene expression or eight protein secretion stimuli
yielded accuracies of 0.67960.073 and 0.64260.119, respectively,
compared to 0.59860.045 and 0.60660.116 across cytokines
(Figures S2, S3, S4). This result is likely due to the higher cross-
correlation observed between cytokines in response to a single
stimulus, compared to the cross-correlation observed in a single
cytokine in response to multiple stimuli.
Second, we observed that the cytokine secretion assay was
superior at discriminating between acute and relapse patients
compared to gene expression. With expression, only the IFN-c
cross-section correctly classified more than one relapse patient
(Figure S2D). Conversely, four cytokine secretion cross-sections
(IL-1, IL-6, IL-10, and TNF-a) and two stimulus cross-sections
(Pam3CSK4 and R848) correctly classified half or more relapse
patients (Figures S3, S4). This result is likely due to better
separation in the response variables between acute and relapse
patients in the cytokine secretion data compared to gene
expression (Figure S5).
Indeed, clustering the patients hierarchically by Euclidean
distance in their gene expression or cytokine secretion profiles, we
found that the gene expression profile for every relapse patient
most closely matches that of an acute patient (Figure 5A).
Similarly, control subject 70005 and acute patient 10288 cross-
cluster with acute and control subjects, respectively. Consequently,
these seven patients are misclassified in over half of the 20 qPCR
Figure 3. Basal PBMC cytokine secretion measured by multi-
plex immunoassay. IL-2, IL-6, IL-8, IL-10, and TNF-a secretion in
unstimulated PBMCs from control donors or acute or relapse brucellosis
patients (asterisk indicates p#0.05). Concentrations indicated by open
circles were extrapolated beyond the assay standard curve and values
in the red shaded zone fell outside the observable range (OOR).
doi:10.1371/journal.pntd.0002424.g003
Figure 4. PBMC cytokine secretion after stimulation measured
by multiplex immunoassay. IL-1b, IL-2, GM-CSF, IFN-c, and TNF-a
protein secretion by from control donors or acute or relapse brucellosis
patients after stimulation with LPS, heat-killed B. melitensis (HKBM), or
the heat-killed B. melitensis vaccine Rev1, as measured by multiplex
immunoassay (asterisk indicates p#0.05). Concentrations indicated by
open circles were extrapolated beyond the assay standard curve and
values in the red shaded zone fell outside the observable range (OOR).
doi:10.1371/journal.pntd.0002424.g004
Ex Vivo Cytokine Signature of Brucellosis
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models identified by forward selection. In contrast, five of the six
relapse patients cluster together according to their cytokine
secretion profile, resulting in significantly better classification
performance (Figure 5B). Among the other patients, control
subject 70005 and acute patient 10288 were again the most often
misclassified, suggesting that these two may be outliers in their
respective patient categories.
Examining the optimal gene expression model identified by
forward selection, we found that it classified 28 of 33 patients
correctly. Distinguishing between acute and relapse patients was
the primary source of misclassification, with 83% relapse
sensitivity (one false negative), but 71% precision (two false
positives) (Figure 6A). In contrast, four cytokine secretion models
correctly classified 32 of 33 patients. These models also classified
five of six relapse patients correctly, but with perfect precision and
fewer variables than gene expression (Figure 6B). Interestingly,
these models all share the following eight response variables: TNF-
a and IL-2 in response to HKBM and LPS, IL-1b in response to
Rev1 and LPS, IFN-c in response to HKBM, and basal IL-6.
Pairing these variables with, for example, IL-1b and GM-CSF in
response to HKBM, or TNF-a and GM-CSF in response to Rev1,
achieves 97% patient classification accuracy. We therefore
propose that these variables constitute an innate immune cytokine
signature for accurate identification of patients at risk for
brucellosis relapse.
Discussion
Here we present evidence that patients with a history of acute-
and-cleared or relapsing brucellosis can be distinguished with a
robust inflammatory cytokine signature even months or years after
successful treatment. Currently, under standard treatment, many
patients experience relapsing brucellosis, the cause of which
remains poorly understood. In this study we stimulated PBMCs
from patients with a past history of acute or relapsing brucellosis
and measured ex vivo innate inflammatory cytokine expression and
secretion to determine if at a clinically normal baseline there was a
cytokine signature that might be associated with relapsing
infection.
Brucella spp. are intracellular pathogens whose effective control
and elimination requires a potent cell-mediated Th1 immune
response [9,21,22]. We found that relapse brucellosis patients
demonstrated higher basal IL-1b and GM-CSF gene expression
compared to control donors, increased IFN-c expression after heat-
killed B. melitensis (HKBM) stimulation and higher TNF-a expres-
sion after LPS stimulation compared to both acute brucellosis
patients and control donors. Surprisingly, this indicates relapse
patients are capable of inducing the expression of cytokines needed
to mount a Th1 response. However increased IL-10 gene expression
after stimulation with HKBM in both acute and relapse brucellosis
patients, but not after LPS stimulation, may suggest a possible
Brucella spp. specific elevated Th2 response. Th2 cytokines like IL-10
have been shown to downregulate immunity to Brucella spp. [23,24].
Additionally, relapse patients produced more TNF-a protein
compared to control donors and secrete more GM-CSF compared
to both groups. Indeed, previous studies indicate GM-CSF
secretion can stimulate IL-1b and TNF-a secretion by monocytes
after in vitro B. abortus challenge [25]. Taken together, the ex vivo
innate immune cytokine expression and secretion of acute or
relapse patients indicates a functional and Th1-dominated
response. IL-2, TNF-a, and IFN-c secretion have previously been
shown to be increased during brucellosis [26,27], and recent
studies also suggest that adequate levels are required for control of
the infection as genetic polymorphisms in these genes may increase
susceptibility to, or duration of, disease [6,28]. In accordance with
our findings, others have shown elevated IFN-c after ex vivo B.
melitensis antigen stimulation in patients less than one year after
diagnosis [29]. Here we confirm that this remains true even several
years after the resolution of infection.
Though gene expression of the Th2 cytokine IL-10 was elevated
in some brucellosis patients, IL-10 protein secretion was not
significantly altered in these patients under any stimulation
condition; IL-4, another important Th2 cytokine, was not highly
secreted in any condition (Supporting Figure S1). However, one
Figure 5. Hierarchical clustering of patients by gene expression or cytokine secretion. Control (green), acute (blue), and relapse (red)
patients were clustered hierarchically by Euclidean distance in their scaled gene expression (A) or cytokine secretion (B) profiles (see Methods).
Response variables are grouped by cytokine, indicated in the left margin, and values are indicated by luminosity. Misclassification rates for each
patient after 20 model selection runs are indicated underneath the corresponding patient code (see Supporting Table S1).
doi:10.1371/journal.pntd.0002424.g005
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key limitation of the study was the multiplex approach used to
determine cytokine protein levels: several of the cytokines
measured in the assay fell above or below the standard range
defined in the manufacturer’s protocol and some concentration
values were extrapolated or not detected. Due to the limited
quantity of patient sample and culture supernatant, individual
optimization for each cytokine and standard in the 10-cytokine kit
was not possible. To address this issue in future studies, multiplex
kits with improved standard ranges could be used or individual
conventional ELISA assays might be useful for key cytokines
which still fall outside the detection of the multiplex assay.
In summary, this study demonstrates that innate immune
cytokine variations can be detected between patients with a history
of acute or relapsing brucellosis and control donors using an ex vivo
assay system. Standard clinical methods for monitoring brucellosis
treatment outcomes remain unreliable: antibody titers used for
serological diagnosis of brucellosis and circulating B. melitensis
DNA load used for diagnosis by PCR, have been shown to persist
for years after successful treatment [30–34]. In contrast, we show
that an ex vivo cytokine signature can accurately distinguish
between relapse and acute patients, and may provide a novel
approach to monitor clinical outcomes. Further work would be
required to validate this ex vivo assay as a method for predicting or
confirming actively relapsing infections.
Supporting Information
Figure S1 PBMC cytokine secretion after stimulation
measured by multiplex immunoassay. Secretion of IL-1b,
IL-2, IL-4, IL-6, IL-8, IL-10, GM-CSF, IFN-c, and TNF-a in
PBMCs from control donors or acute or relapse brucellosis
patients without stimulation (basal) or after stimulation with
Pam3CSK4, Poly(I:C), LPS, R848, CpG, HKBM, or Rev1.
Concentrations indicated by open circles were extrapolated
beyond the assay standard curve and values in the red shaded
zone fell outside the observable range (OOR).
(TIF)
Figure S2 Classifiers identified by forward model
selection using all cytokine (A–E) and stimulus (F–I)
cross-sections in the gene expression data. Each panel
illustrates the model selection (left) and resulting classifier
performance (right) for cytokines (A) GM-CSF (B) IL-10 (C)
TNF- a (D) IFN- c and (E) IL-10 and stimuli (F) Basal (no stimulus)
(G) HKBM (H) LPS and (I) R848. For model selection, the
accuracy of the resulting classifier is given as a function of the
number of variables incorporated. The results of 20 selections are
shown for each cross-section, with the best-performing classifier
highlighted in bold. The identity of each variable incorporated
into the best-performing classifier is indicated above its corre-
sponding index. Zero features is equivalent to random guessing.
For each cross-section, the confusion matrix generated by the best-
performing classifier is shown at right. This matrix gives the
proportion of the 11 (C)ontrol, 16 (A)cute, and 6 (R)elapse patients
that were correctly and incorrectly classified.
(TIF)
Figure S3 Classifiers identified by forward model
selection for all cytokine cross-sections in the cytokine
secretion data. Each panel illustrates the model selection (left)
and resulting classifier performance (right) for cytokines (A) IL-1b
(B) IL-2 (C) IL-4 (D) IL-5 (E) IL-6 (F) IL-8 (G) IL-10 (H) GM-CSF
(I) IFN- c and (J) TNF- a. See Figure S2 for details.
(TIF)
Figure S4 Classifiers identified by forward model
selection for all stimulus cross-sections in the cytokine
Figure 6. Model selection and classification results. Response variables were selected and a linear discriminant classifier was trained using the
transformed gene expression (A) or cytokine secretion data (B). The left panels show the results of 20 model selection runs, with the best-performing
classifier highlighted in color. The variable included after each step in the forward selection is listed for the optimal model. Zero features is equivalent
to random guessing. The center column shows all 33 patients after being mapped by the first (LD1) and second (LD2) linear discriminant functions
used by the best-performing classifier. Classification performance is summarized by the confusion matrix on the right. This matrix gives the
proportion of (C)ontrol, (A)cute, and (R)elapse patients that were correctly (on-diagonal) and incorrectly classified (off-diagonal).
doi:10.1371/journal.pntd.0002424.g006
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secretion data. Each panel illustrates the model selection (left)
and resulting classifier performance (right) for stimuli (A) Basal (no
stimulus) (B) Pam3CSK4 (C) Poly(I:C) (D) LPS (E) R848 (F) CpG
(G) HKBM and (H) Rev1. See Figure S2 for details.
(TIF)
Figure S5 Data separation in the gene expression and
cytokine secretion data sets. Scaled, log10-transformed
response variables were taken from the full gene expression data
set (left) and the partial, imputed cytokine secretion data set (right),
where no variable was missing more than four values and no
patient category was missing more than one value (see Methods).
Variables for which relapse patients exhibited a mean value less
than that of control subjects were inverted (multiplied by 21). The
density of the resulting variables was estimated using the ‘density’
function in R, then overlayed by patient category: control (green),
acute (blue) and relapse (red).
(TIF)
Table S1 Clinical characteristics of patient population.
(XLS)
Table S2 Primers used for quantitative real-time PCR.
(XLS)
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